bluebird bio, Inc. (BLUE) Insider Sells $133,825.00 in Stock
bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 1,250 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $107.06, for a total value of $133,825.00. Following the sale, the insider now directly owns 28,555 shares of the company’s stock, valued at $3,057,098.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
bluebird bio, Inc. (NASDAQ BLUE) opened at 130.85 on Friday. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $133.10. The stock has a 50 day moving average price of $98.27 and a 200 day moving average price of $93.20. The stock’s market cap is $5.97 billion.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. During the same quarter last year, the business posted ($1.59) EPS. bluebird bio’s quarterly revenue was up 977.4% compared to the same quarter last year. On average, equities analysts predict that bluebird bio, Inc. will post ($6.82) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/02/bluebird-bio-inc-blue-insider-sells-133825-00-in-stock.html.
Large investors have recently bought and sold shares of the stock. FMR LLC raised its stake in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock worth $556,918,000 after buying an additional 37,742 shares during the period. Advisors Asset Management Inc. bought a new stake in bluebird bio during the first quarter worth about $858,000. Winfield Associates Inc. raised its stake in bluebird bio by 6.1% in the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after buying an additional 162 shares during the period. Macquarie Group Ltd. bought a new stake in bluebird bio during the fourth quarter worth about $703,000. Finally, Alliancebernstein L.P. raised its stake in bluebird bio by 50.1% in the first quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock worth $7,805,000 after buying an additional 28,640 shares during the period.
A number of analysts recently issued reports on BLUE shares. Evercore ISI started coverage on bluebird bio in a research report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price objective for the company. Wedbush restated an “outperform” rating and set a $135.00 target price (up from $121.00) on shares of bluebird bio in a report on Friday. BTIG Research cut bluebird bio from a “buy” rating to a “neutral” rating and raised their target price for the company from $37.05 to $108.25 in a report on Friday, June 30th. Zacks Investment Research upgraded bluebird bio from a “sell” rating to a “hold” rating in a report on Monday, May 8th. Finally, Cowen and Company restated an “outperform” rating on shares of bluebird bio in a report on Friday, June 9th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $102.68.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.